Lowering LINC01296 levels can diminish the expression of miR-143-3p's target gene, ATG2B, thereby enhancing paclitaxel sensitivity in NSCLC and offering a promising approach for NSCLC chemotherapy in clinical settings [18]. This evidence concerns the gene ATG2B and non-small cell lung carcinoma.